Heterogeneity of Alzheimer’s disease: consequence for drug trials?

BACKGROUND: Alzheimer’s disease is a heterogenous disorder with multiple phenotypes and genotypes, although they eventually converge to a final common clinicopathological endpoint. However, Alzheimer’s disease drug trials do not account for the heterogeneity of the disease in trial design, impeding...

Descripción completa

Detalles Bibliográficos
Autores principales: Devi, Gayatri, Scheltens, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300886/
https://www.ncbi.nlm.nih.gov/pubmed/30567585
http://dx.doi.org/10.1186/s13195-018-0455-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300886/
https://www.ncbi.nlm.nih.gov/pubmed/30567585
http://dx.doi.org/10.1186/s13195-018-0455-y

Ejemplares similares